ストックスクリーナーアプリを入手
47.09
1.42%
0.66
アフターアワーズ：
47.01
-0.08
-0.17%
前日終値:
$46.43
開ける：
$47.25
24時間の取引高:
1.08M
Relative Volume:
0.57
時価総額：
$4.52B
収益：
$3.51M
当期純損益:
$-581.60M
株価収益率:
-7.2285
EPS:
-6.5145
ネットキャッシュフロー:
$-345.93M
1週間 パフォーマンス:
-1.26%
1か月 パフォーマンス:
-14.69%
6か月 パフォーマンス:
-21.93%
1年 パフォーマンス:
+15.16%
1日の値動き範囲:
$47.05
$48.30
1週間の範囲:
$45.12
$48.30
52週間の値動き範囲:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Compare CRSP vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
47.09 | 4.46B | 3.51M | -581.60M | -345.93M | -6.5145 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-18 | 開始されました | JP Morgan | Overweight |
| 2025-02-14 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-02-12 | アップグレード | TD Cowen | Sell → Hold |
| 2025-02-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-08-02 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-28 | 再開されました | Guggenheim | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-11 | ダウングレード | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 開始されました | Mizuho | Buy |
| 2023-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-04-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-03-17 | 開始されました | Bryan Garnier | Buy |
| 2023-03-07 | 開始されました | Robert W. Baird | Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-08-09 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | アップグレード | Citigroup | Sell → Neutral |
| 2021-04-21 | アップグレード | Jefferies | Hold → Buy |
| 2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-12-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2020-12-10 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-10 | 繰り返されました | Needham | Buy |
| 2020-12-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-07-28 | 繰り返されました | Needham | Buy |
| 2020-07-14 | 開始されました | SunTrust | Buy |
| 2020-06-15 | 繰り返されました | Canaccord Genuity | Buy |
| 2020-03-05 | 開始されました | Stifel | Hold |
| 2020-02-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-19 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 開始されました | Jefferies | Buy |
| 2019-07-26 | 開始されました | Canaccord Genuity | Buy |
| 2019-06-10 | 開始されました | ROTH Capital | Buy |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-14 | 開始されました | William Blair | Mkt Perform |
| 2019-01-28 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-22 | ダウングレード | Citigroup | Neutral → Sell |
すべてを表示
Crispr Therapeutics Ag (CRSP) 最新ニュース
Why CRISPR Therapeutics AG (CRSP) Performed Better Than the Market Today - Bitget
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today - Yahoo Finance UK
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 3,182 Shares - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 10,020 Shares - MarketBeat
Crispr Therapeutics Insider Sold Shares Worth $468,736, According to a Recent SEC Filing - marketscreener.com
CRISPR (CRSP) GC granted options, RSUs; sells shares for taxes - Stock Titan
CRISPR Therapeutics (CRSP) CEO gets major equity awards, sells shares for taxes - Stock Titan
[Form 4] CRISPR Therapeutics AG Insider Trading Activity - Stock Titan
CRISPR Therapeutics (NASDAQ: CRSP) grants CMO stock options and RSUs - Stock Titan
CRISPR Therapeutics Hits Day Low of $45.88 Amid Price Pressure - Markets Mojo
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning - Benzinga
What's going on with CRISPR Therapeutics stock today? - MSN
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know - MSN
JPMorgan Chase & Co. Has $38.46 Million Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Here is why CRISPR Therapeutics (CRSP) appears so good - MSN
CRISPR Therapeutics AG (CRSP) registers a bigger fall than the market: Important facts to note - MSN
This Cathie Wood Stock Is Down 36% Over the Past 2 Years. She Still Can’t Get Enough. - Barchart
Is CRISPR Therapeutics Stock a Buy Now? - The Motley Fool
Assessing CRISPR Therapeutics (CRSP) Valuation After CASGEVY Traction And US$600m Convertible Notes Raise - Sahm
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance Singapore
CRISPR Therapeutics gains amid takeover speculation - MSN
CRISPR Therapeutics AG (CRSP) falls more steeply than broader market: What investors need to know - MSN
CRISPR Therapeutics AG (CRSP) Declines Sharply Compared to Overall Market: Essential Information for Investors - Bitget
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
CRISPR Therapeutics AG Bonds — Corporate Bond Rates - TradingView
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - MSN
(CRSP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Piper Sandler raises CRISPR Therapeutics price target on cash raise By Investing.com - Investing.com South Africa
Volatility Watch: Is CRISPR Therapeutics AG showing insider buyingInsider Selling & Proven Capital Preservation Tips - baoquankhu1.vn
CRISPR Therapeutics (CRSP) Is Down 5.1% After $550M Convertible Notes OfferingHas The Bull Case Changed? - simplywall.st
Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 10,349 Shares of Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Insider Naimish Patel Sells 3,150 Shares of Stock - MarketBeat
CRISPR Therapeutics (NASDAQ: CRSP) CMO vests RSUs, mandated tax sale - Stock Titan
CRISPR Therapeutics (NASDAQ: CRSP) CFO covers RSU taxes with share sale and gift - Stock Titan
CRISPR Therapeutics (NASDAQ: CRSP) GC sells shares for tax withholding - Stock Titan
CRISPR Therapeutics (CRSP) CEO logs RSU vesting and tax-driven share sale - Stock Titan
Best CRISPR Companies for 2026 and How to Invest in Them - The Motley Fool
Crispr Therapeutics Completes $600 Million Convertible Notes Offering - The Globe and Mail
Goodwin Guides CRISPR Therapeutics On Pricing $550 Million Upsized Convertible Senior Notes Offering - Mondaq
Piper Sandler Raises Price Target for CRSP to $110, Reiterates O - GuruFocus
Is CRISPR Therapeutics (CRSP) the best gene-editing stock to buy now? - MSN
Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now? - Insider Monkey
CRISPR Therapeutics (NASDAQ:CRSP) Receives Overweight Rating from Piper Sandler - MarketBeat
Piper Sandler raises CRISPR Therapeutics price target on cash raise - Investing.com
CRISPR Therapeutics (NASDAQ: CRSP) sells $600M 2031 convertible notes - Stock Titan
CRISPR Therapeutics AG Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ark Invest Increases Holdings in CRISPR Therapeutics (CRSP) - GuruFocus
Investors heavily search CRISPR Therapeutics AG (CRSP): Here is what you need to know - MSN
Crispr Therapeutics Ag (CRSP) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):